Ionis Pharmaceuticals IONS Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent?
- Ionis Pharmaceuticals (IONS) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent of -24.7% in Q4 2025.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent mean?
- The percentage point impact on the effective tax rate caused by changes in the valuation allowance for deferred tax assets.
- How do you interpret effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent?
- High values indicate that tax rate volatility is driven by accounting adjustments for asset recoverability rather than operational tax changes.
- How does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent compare across companies?
- Standard reconciliation item in corporate tax disclosures for companies with significant net operating loss carryforwards.